We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Treatment of Subclinical Hyperthyroidism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00213720
Recruitment Status : Active, not recruiting
First Posted : September 21, 2005
Last Update Posted : September 8, 2017
Information provided by (Responsible Party):
University Hospital, Strasbourg, France

Brief Summary:
Objective: To determine if the treatment of subclinical hyperthyroidism will reduce the rate of atrial fibrillation, the main complication of this condition.

Condition or disease
Subclinical Hyperthyroidism Atrial Fibrillation

Detailed Description:
Randomized open-labelled multicentre study comparing radioiodine vs medical supervision without treatment

Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Place de l'Iode RadioActif Dans l'HyperThyroïdiE Sub-clinique (PIRHATES)/ Evaluation of the Interest of Subclinical Hyperthyroidism Treatment
Study Start Date : August 2005
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Biospecimen Retention:   Samples Without DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients referred to tertiary hospitals for advice on thyroïd disease

Inclusion Criteria:

  • Men and women aged 50 and greater
  • Isolated decreased thyroid-stimulating hormone (TSH) with normal FT4 and FT3 levels

Exclusion Criteria:

  • Iodide overload
  • Non sinusal heart rhythm
  • Severe heart disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213720

Patrick Roger
Bordeaux, France
Philippe Thiéblot
Clermont-Ferrand, France
Jean-Marcel Brun
Dijon, France
Jean-Louis Wemeau
Lille, France
Marie-Pierre Teissier
Limoges, France
Jacques Orgiazzi
Lyon, France
Bernard Conte-Delvox
Marseille, France
CH de Montbrison
Montbrison, France, 42605
Jacques Bringer
Montpellier, France
Marc Klein
Nancy, France
Michel Rodier
Nimes, France
Laurence Leenhardt
Paris, France
Richard Marechaud
Poitiers, France
Brigitte Delemer
Reims, France
Claire Schvartz
Reims, France
Didier Maugendre
Rennes, France
Jean-Marc Kuhn
Rouen, France
Bruno Estour
Saint-Etienne, France
Centre Paul Strauss
Strasbourg, France, 67000
Hopitaux Universitaires de Strasbourg
Strasbourg, France
Philippe Caron
Toulouse, France
Pierre Lecomte
Tours, France
Sponsors and Collaborators
University Hospital, Strasbourg, France
Principal Investigator: Bernard Goichot, MD Hopitaux Universitaires de Strasbourg

Responsible Party: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT00213720     History of Changes
Other Study ID Numbers: 3463
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: September 8, 2017
Last Verified: September 2017

Keywords provided by University Hospital, Strasbourg, France:
atrial fibrillation
quality of life
radioiodine treatment

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Thyroid Diseases
Endocrine System Diseases